Holly Pitt Young highlighted Nat Hentoff's retort to Nobel Economics Prize winner Paul Krugman's use of...whoops! Sarah Palin's aptly named death panels in a cost/benefit discussion of the use of certain drugs and/or surgical techniques in the coming health care deformity of Obamacare. As she noted, next week the Food and Drug Administration will determine whether insurance and Medicare should provide breast cancer patients and their doctors the option of using Avastin -- a late-stage cancer drug that has been proven to extend life. Should the FDA deny coverage for the drug because of its cost, it will be apparent that Krugman and his ilk are winning to battle to ration care in America. Rest assured we are watching the outcome. Keep watching Ms. Young. Like any drug against a deadly disease, Avastin isn't perfect; the New York Times had an extensive analysis of its promise and problems. And thanks to the Obamacare deformity, here's another kicker--Avastin will probably be...(Read Full Post)